Company intelligence / Profile preview

Alpha Biomedical

Ownership: Private
Employees: ~49
Development stage: Other

Overview

No human data yet; preclinical progress reported across several modalities/programs. The company is preparing for first-in-human trials of its CAR-T and NK cell therapies targeting cancer, with GMP manufacturing capabilities coming online in Malaysia by late 2025. Exosome and MSC stem cell programs are also under development.

Therapeutic areas: OncologyOther
Modalities: Cell therapyMesenchymal stem cellsNatural killer cellsExosome-based therapyCAR-T cell therapy
Industry: Biotech

Drug pipeline

4 assets

ABS-005

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

Technology transfer agreement with a US biotech company for CAR-T technologyGlobal research partnerships planned from late–2026 onward

Beyond the preview

Go deeper on Alpha Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha Biomedical.

Explore the full profile